Merck KGaA Q2 2026: 4.1% Organic Growth Looks Strong-Until You See the Profit Trap

Q2 2026 splits the view on Merck KGaA

This earnings report is easy to interpret in two ways.

The positive read is straightforward: Merck posted organic sales +4.1% and EBITDA pre growth of 9.3%, with momentum coming from Life Science and Electronics. That is the kind of top- and middle-line improvement bulls will point to as evidence the operating engine is still working.

The cautionary read is just as clear: profit after tax fell 24.7% even as revenue and EBITDA pre improved. That disconnect is the real story here, because it raises the question of whether the quarter was genuinely healthy or merely strong in places.

What investors are actually debating

• Bull case: Life Science and Electronics are still compounding, and the weaker parts of the business may prove temporary.
• Bear case: EBIT fell 15.5%, Healthcare kept slipping, and better revenue growth has not yet translated into cleaner earnings.

My read is that this is a watchlist quarter, not a broken one. The next move depends on whether management can show that the profit leak is temporary or something more structural.

Life Science and Electronics are carrying the quarter

The central valuation question is simple: which businesses are actually compounding?

The growth stack is broadening

The quarter matters because the strength is not concentrated in a single niche. Life Science grew net sales 6.4%, with Process Solutions posting 14.7% organic growth. Electronics also contributed, with 11.7% organic growth. This looks less like a one-product rescue and more like multiple businesses moving in the same direction.

That pattern also matches the earlier part of the year. In Q1, the upgrade was tied to Process Solutions and Semiconductor Materials. When the same core areas keep showing up as growth drivers across quarters, the trend starts to look more structural and less incidental.

Why that matters for valuation

If those businesses can keep scaling, Merck becomes harder to value like a plain pharma company. Life Science and Electronics give the group exposure to longer-duration science and technology spending cycles, while Healthcare now introduces more volatility.

Management has already signaled that future growth will need to come from that broader stack. The upgraded 2026 outlook assumes no Mavenclad sales in the U.S. from August 2026, which raises the importance of Life Science and Electronics even further.

What to watch next

• Process Solutions remains the clearest torque driver inside Life Science.
• Electronics keeps advancing despite FX pressure and the divestment of Surface Solutions.
• Management continues to frame the planned Bio-Techne acquisition as a way to strengthen the core stack, not offset weakness elsewhere.

Healthcare is still the pressure point

Healthcare is where the bull case encounters its biggest resistance.

The numbers are moving the wrong way

Merck still delivered organic sales +4.1% and EBITDA pre growth of 9.3% at the group level, but Healthcare went the other direction: organic sales declined 3.4% and Healthcare EBITDA pre fell 4.6%. That is the pressure point in the report.

What is driving the drag

The underlying details are fairly explicit. Healthcare included a 5.7% organic decline amid higher R&D spending. Specialty Care sales fell 5.8% organically, and Mavenclad in the U.S. dropped 10.2% organically amid generic competition. Bulls can argue that those issues are confined to one part of the portfolio. Bears will argue that they matter more because they are hitting both revenue and profitability.

The key signal is that EBIT fell 15.5%. If Healthcare continues to slip, that profit leak can keep limiting consolidation even if the other segments stay strong.

What would change the read

• Improves the thesis: Healthcare stops sliding after the loss of Mavenclad U.S. sales, and Specialty Care stabilizes.
• Delays the rerating: Healthcare organic sales declined 3.4% becomes a recurring trend, Healthcare EBITDA pre fell 4.6% worsens, and EBIT fell 15.5% remains under pressure.

Guidance is the line between interest and confidence

Upgraded guidance is what turns this from an interesting quarter into a more credible setup.

The bull and bear paths

The bull case is straightforward: if Merck hits 2026 guidance of €21.0–€21.8 billion net sales and EBITDA pre of €5.9–€6.3 billion after a quarter of organic sales +4.1% and EBITDA pre +9.3%, the market will have a stronger basis for expecting profit catch-up. That view is more credible because the core engines also showed up in Q1, when growth was tied to Process Solutions and Semiconductor Materials.

The bear case is just as clear. The guidance already assumes no Mavenclad sales in the U.S. from August 2026. If Life Science and Electronics soften even modestly, or if Healthcare continues pressuring consolidation, investors are more likely to focus on guidance risk than on a future rerating.

For now, this looks like a watchlist name rather than a fully confirmed story: operating momentum is visible, but earnings translation still needs to be proven.